QCM
BEAM icon

QRG Capital Management’s Beam Therapeutics BEAM Stock Holding History

QRG Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,635
Closed -$325K – 1121
2025
Q1 		$325K Sell
16,635
-870
-5% -$22.8K ﹤0.01% 893
2024
Q4 		$434K Sell
17,505
-3,303
-16% -$84.3K ﹤0.01% 799
2024
Q3 		$510K Sell
20,808
-422
-2% -$10.9K 0.01% 770
2024
Q2 		$497K Sell
21,230
-1,806
-8% -$44.4K 0.01% 733
2024
Q1 		$761K Buy
23,036
+7,176
+45% +$224K 0.01% 621
2023
Q4 		$432K Buy
15,860
+3,035
+24% +$75.4K 0.01% 769
2023
Q3 		$308K Buy
+12,825
New +$344K 0.01% 799

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

QRG Capital Management's BEAM Position: Q2 2025 in Review

QRG Capital Management sold out of Beam Therapeutics (BEAM) in Q2 2025, closing a stake of 16,635 shares — an estimated $325K sold.

QRG Capital Management first reported a position in BEAM in Q3 2023 and held it in 7 quarters. The position peaked at $761K in Q1 2024. 217 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

  • QRG Capital Management reported no remaining Beam Therapeutics position as of Q2 2025 after selling out during the quarter.
  • QRG Capital Management sold 16,635 Beam Therapeutics shares in Q2 2025, an estimated $325K.
  • QRG Capital Management first reported a position in Beam Therapeutics in Q3 2023 and held it in 7 quarters.
  • QRG Capital Management's Beam Therapeutics position peaked at $761K in Q1 2024.
  • 217 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on QRG Capital Management's 13F filing for Q2 2025, filed 21 Jul 2025.